Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR4 | P61073 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Thiomorpholine SCHEMBL28234116 | 0.90 | CXCR4 (0.60) | CXCR4SMN1; SMN2ALDH1A1 | |
| SCHEMBL12100700 | 0.90 | — | — | |
| SCHEMBL138572 | 0.90 | — | — | |
| SCHEMBL12882833 | 0.90 | CXCR4 (0.41) | CXCR4SMN1; SMN2ALDH1A1 | |
| SCHEMBL7203635 | 0.90 | CXCR4 (0.33) | CXCR4SMN1; SMN2ALDH1A1 | |
| SCHEMBL15355221 | 0.88 | CXCR4 (0.47) | CXCR4SMN1; SMN2ALDH1A1 | |
| SCHEMBL869844 | 0.88 | — | — | |
| Hydrochloric Acid SCHEMBL1870653 | 0.88 | — | — | |
| SCHEMBL29016828 | 0.87 | ALDH1A1 (0.53) | CXCR4SMN1; SMN2ALDH1A1 | |
| Thiomorpholine SCHEMBL6624599 | 0.87 | ALDH1A1 (0.53) | CXCR4SMN1; SMN2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230321287-A1 | RADIOLABELLED GRPR-ANTAGONIST FOR USE AS THERAGNOSTIC | NOVARTIS AG (CH) | 2023-10-12 | — | — | US | disclosed |
| US-20230321287-A1 | RADIOLABELLED GRPR-ANTAGONIST FOR USE AS THERAGNOSTIC | NOVARTIS AG (CH) | 2023-10-12 | — | — | US | disclosed |
| US-20220008568-A1 | Radiolabeled GRPR-Antagonists for Diagnostic Imaging and Treatment of GRPR-Positive Cancer | ADVANCED ACCELERATOR APPLICATIONS INTERNATIONAL SA (CH) | 2022-01-13 | — | — | US | disclosed |
| US-20220008566-A1 | Pharmaceutical Composition Comprising a Radiolabeled GRPR Antagonist and a Surfactant | ADVANCED ACCELERATOR APPLICATIONS INTERNATIONAL SA (CH) | 2022-01-13 | — | — | US | disclosed |
| US-20210346529-A1 | Radiolabeled GRPR-Antagonists for Diagnostic Imaging and Treatment of GRPR-Positive Cancer | ADVANCED ACCELERATOR APPLICATIONS INTERNATIONAL SA (CH) | 2021-11-11 | — | — | US | disclosed |
| US-20210346528-A1 | Radiolabeled GRPR-Antagonists for Diagnostic Imaging and Treatment of GRPR-Positive Cancer | ADVANCED ACCELERATOR APPLICATIONS INTERNATIONAL SA (CH) | 2021-11-11 | — | — | US | disclosed |
| US-11083805-B2 | Radiolabeled GRPR-antagonists for diagnostic imaging and treatment of GRPR-positive cancer | ADVANCED ACCELERATOR APPLICATIONS INTERNATIONAL SA (CH) | 2021-08-10 | — | — | US | disclosed |
| EP-3536347-A1 | GRPR-ANTAGONISTS FOR DETECTION, DIAGNOSIS AND TREATMENT OF GRPR-POSITIVE CANCER | Advanced Accelerator Applications USA, Inc. (US) | 2019-09-11 | — | — | EP | disclosed |
| EP-2900279-B1 | GRPR-ANTAGONISTS FOR DETECTION, DIAGNOSIS AND TREATMENT OF GRPR-POSITIVE CANCER | ADVANCED ACCELERATOR APPLICATIONS USA INC (US) | 2019-08-14 | — | — | EP | disclosed |
| US-20180133349-A1 | Radiolabeled GRPR-Antagonists For Diagnostic Imaging and Treatment of GRPR-Positive Cancer | ADVANCED ACCELERATOR APPLICATIONS INTERNATIONAL SA (CH) | 2018-05-17 | — | — | US | disclosed |
| US-20180133349-A1 | Radiolabeled GRPR-Antagonists For Diagnostic Imaging and Treatment of GRPR-Positive Cancer | ADVANCED ACCELERATOR APPLICATIONS INTERNATIONAL SA (CH) | 2018-05-17 | — | — | US | disclosed |
| US-9839703-B2 | Radiolabeled GRPR-antagonists for diagnostic imaging and treatment of GRPR-positive cancer | ADVANCED ACCELERATOR APPLICATIONS USA, INC. (US) | 2017-12-12 | — | — | US | disclosed |
| US-9839703-B2 | Radiolabeled GRPR-antagonists for diagnostic imaging and treatment of GRPR-positive cancer | ADVANCED ACCELERATOR APPLICATIONS USA, INC. (US) | 2017-12-12 | — | — | US | disclosed |
| US-20150265732-A1 | GRPR-ANTAGONISTS FOR DETECTION, DIAGNOSIS AND TREATMENT OF GRPR-POSITIVE CANCER | ADVANCED ACCELERATOR APPLICATIONS INTERNATIONAL SA (CH) | 2015-09-24 | — | — | US | disclosed |
| US-20150265732-A1 | GRPR-ANTAGONISTS FOR DETECTION, DIAGNOSIS AND TREATMENT OF GRPR-POSITIVE CANCER | ADVANCED ACCELERATOR APPLICATIONS INTERNATIONAL SA (CH) | 2015-09-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150265732-A1 | GRPR-ANTAGONISTS FOR DETECTION, DIAGNOSIS AND TREATMENT OF GRPR-POSITIVE CANCER | GRPR, GIPR, CCKBR | CXCR4 880/4885SMN1; SMN2 4210/4885ALDH1A1 4001/4885 |
| US-20180133349-A1 | Radiolabeled GRPR-Antagonists For Diagnostic Imaging and Treatment of GRPR-Positive Cancer | GRPR, GIPR, CCKBR | CXCR4 904/4885SMN1; SMN2 3979/4885ALDH1A1 4088/4885 |
| US-20210346528-A1 | Radiolabeled GRPR-Antagonists for Diagnostic Imaging and Treatment of GRPR-Positive Cancer | GRPR, GIPR, CCKBR | CXCR4 904/4885SMN1; SMN2 3979/4885ALDH1A1 4088/4885 |
| US-20210346529-A1 | Radiolabeled GRPR-Antagonists for Diagnostic Imaging and Treatment of GRPR-Positive Cancer | GRPR, GIPR, CCKBR | CXCR4 904/4885SMN1; SMN2 3979/4885ALDH1A1 4088/4885 |
| US-20220008566-A1 | Pharmaceutical Composition Comprising a Radiolabeled GRPR Antagonist and a Surfactant | GRPR, GIPR, SCTR | CXCR4 946/4885SMN1; SMN2 3404/4885ALDH1A1 4771/4885 |
| US-20220008568-A1 | Radiolabeled GRPR-Antagonists for Diagnostic Imaging and Treatment of GRPR-Positive Cancer | GRPR, GIPR, CCKBR | CXCR4 904/4885SMN1; SMN2 3979/4885ALDH1A1 4088/4885 |
| US-11083805-B2 | Radiolabeled GRPR-antagonists for diagnostic imaging and treatment of GRPR-positive cancer | GRPR, GIPR, CCKBR | CXCR4 904/4885SMN1; SMN2 3979/4885ALDH1A1 4088/4885 |
| US-20230321287-A1 | RADIOLABELLED GRPR-ANTAGONIST FOR USE AS THERAGNOSTIC | GRPR, GIPR, SCTR | CXCR4 928/4885SMN1; SMN2 4348/4885ALDH1A1 4782/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.